| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2006.
NEWS |
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment
| The first 10% of the full text of this article appears below. |
Oncolytic virus research got a welcome boost last November when Chinese regulators approved the world's first oncolytic viral therapy for cancer, Shanghai Sunway Biotech's genetically modified adenovirus H101.
"It's fantastic for the field," said John Bell, Ph.D., of the Ottawa Health Research Institute in Canada. "We needed to have something that was a success, and so I think this is a good first start."
| |||||||||||
Oncolytic viruses are live viruses that selectively kill cancer cells. Shanghai Sunway Biotech expects to begin marketing H101 in July for treating head and neck cancer. The company is also testing the virus in lung cancer and has bought the rights to Onyx-15, an almost identical virus that Onyx Pharmaceuticals took into phase III trials in 2000 but later dropped after its marketing partner bailed out.
Now the Chinese effort has breathed new life into the Onyx virus. Sunway's next step, says
Virus Interruptus
Final Judgment
A Rebounding Field
Overcoming Obstacles
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Thomas, R. S. Broughton, F. D. Goodrum, and D. A. Ornelles E4orf1 Limits the Oncolytic Potential of the E1B-55K Deletion Mutant Adenovirus J. Virol., March 15, 2009; 83(6): 2406 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Dhar, J. F. Spencer, K. Toth, and W. S. M. Wold Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters J. Virol., March 1, 2009; 83(5): 2130 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Shashkova, K. Doronin, J. S. Senac, and M. A. Barry Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus Cancer Res., July 15, 2008; 68(14): 5896 - 5904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, C. Su, H. Cao, K. Li, J. Chen, L. Jiang, Q. Zhang, X. Wu, X. Jia, Y. Liu, et al. A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers Mol. Cancer Ther., June 1, 2008; 7(6): 1598 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Verbeek, T. D. Southgate, D. E. Gilham, and G. P. Margison O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy Br. Med. Bull., March 1, 2008; 85(1): 17 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Curtin, M. Candolfi, W. Xiong, P. R. Lowenstein, and M. G. Castro Turning the gene tap off; implications of regulating gene expression for cancer therapeutics Mol. Cancer Ther., March 1, 2008; 7(3): 439 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ungerechts, C. Springfeld, M. E. Frenzke, J. Lampe, P. B. Johnston, W. B. Parker, E. J. Sorscher, and R. Cattaneo Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine Cancer Res., November 15, 2007; 67(22): 10939 - 10947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-C. Liu and D. Kirn Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future Directions Cancer Res., January 15, 2007; 67(2): 429 - 432. [Abstract] [Full Text] [PDF]
|
|